ATE389724T1 - Menschliche dnase i hyperaktive varianten - Google Patents

Menschliche dnase i hyperaktive varianten

Info

Publication number
ATE389724T1
ATE389724T1 AT97929686T AT97929686T ATE389724T1 AT E389724 T1 ATE389724 T1 AT E389724T1 AT 97929686 T AT97929686 T AT 97929686T AT 97929686 T AT97929686 T AT 97929686T AT E389724 T1 ATE389724 T1 AT E389724T1
Authority
AT
Austria
Prior art keywords
variants
human dnase
hyperactive
hyperactive variants
relates
Prior art date
Application number
AT97929686T
Other languages
English (en)
Inventor
Robert LAZARUS
Clark Pan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389724T1 publication Critical patent/ATE389724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97929686T 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten ATE389724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/663,831 US6391607B1 (en) 1996-06-14 1996-06-14 Human DNase I hyperactive variants

Publications (1)

Publication Number Publication Date
ATE389724T1 true ATE389724T1 (de) 2008-04-15

Family

ID=24663430

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97929686T ATE389724T1 (de) 1996-06-14 1997-06-09 Menschliche dnase i hyperaktive varianten

Country Status (12)

Country Link
US (4) US6391607B1 (de)
EP (1) EP0910647B1 (de)
JP (1) JP3468778B2 (de)
AT (1) ATE389724T1 (de)
AU (1) AU737618B2 (de)
CA (1) CA2257133C (de)
DE (1) DE69738581T2 (de)
DK (1) DK0910647T3 (de)
ES (1) ES2301180T3 (de)
NZ (1) NZ333128A (de)
PT (1) PT910647E (de)
WO (1) WO1997047751A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
CN101195025A (zh) * 2001-03-15 2008-06-11 雷金纳克斯生物制药公司 胸腺素β4、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US20050016668A1 (en) * 2003-06-16 2005-01-27 Lori Powers Method and apparatus for cutting through an outer layer on a container
RU2269359C2 (ru) * 2004-03-12 2006-02-10 Дмитрий Дмитриевич Генкин Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
RU2269358C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) * 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
AU2003298972A1 (en) * 2003-07-14 2005-02-04 Dmitry Dmitrievich Genkin Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
WO2005115444A2 (en) * 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7595179B2 (en) * 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US8916151B2 (en) * 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
JP5372769B2 (ja) * 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
CA2757951A1 (en) * 2009-04-10 2010-10-14 Biorad Laboratories, Inc. Modified dnase compositions and methods of use thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
KR20240007725A (ko) 2009-11-02 2024-01-16 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
DK2826860T3 (en) 2010-04-23 2018-12-03 Univ Massachusetts CNS targeting AAV vectors and methods for their use
EP2468870A1 (de) 2010-12-23 2012-06-27 Philip Morris Products S.A. Verfahren zur Expression von Desoxyribonuklease in Pflanzen
AU2012249360B2 (en) 2011-04-29 2015-12-24 University Of Washington Therapeutic nuclease compositions and methods
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
ES2759252T3 (es) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
WO2016065001A1 (en) 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
WO2016069889A1 (en) 2014-10-31 2016-05-06 Resolve Therapeutics, Llc Therapeutic nuclease-transferrin fusions and methods
IL253208B2 (en) 2015-01-04 2023-03-01 Protalix Ltd Converted DNase and its uses
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
US20180214576A1 (en) * 2015-07-28 2018-08-02 University Of Massachusetts Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
EP3413928B1 (de) 2016-02-12 2022-04-20 University of Massachusetts Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
MA46916A (fr) 2016-11-17 2019-09-25 Iovance Biotherapeutics Inc Resttumorinfiltrierende lymphozyten und verfahren zur herstellung und verwendung davon
EP3351263A1 (de) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmazeutische zusammensetzung zur behandlung oder prävention von gewebeadhäsion
AU2018318313B2 (en) 2017-08-18 2025-01-23 Neutrolis Inc. Engineered DNase enzymes and use in therapy
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
AU2020204992A1 (en) 2019-01-04 2021-07-15 Resolve Therapeutics, Llc Treatment of sjogren's disease with nuclease fusion proteins
EP4041880A4 (de) 2019-10-07 2023-08-30 Texas Tech University System Mutante dnase1l3 mit verbesserter serum-halbwertszeit
WO2021089860A2 (en) * 2019-11-08 2021-05-14 Thermo Fisher Scientific Baltics Uab Deoxyribonuclease variants and uses thereof
EP4171614A1 (de) 2020-06-29 2023-05-03 Resolve Therapeutics, LLC Behandlung des sjögren-syndroms mit nukleasefusionsproteinen
IL301970A (en) 2020-10-07 2023-06-01 Protalix Ltd Long-acting dnase
CA3207134A1 (en) 2021-02-19 2022-08-25 Jeffrey A. Ledbetter Dnase fusion polypeptides and related compositions and methods
US11993792B2 (en) 2021-05-27 2024-05-28 New England Biolabs, Inc. DNase I variants, compositions, methods, and kits
WO2025147696A1 (en) 2024-01-05 2025-07-10 Resolve Therapeutics, Llc Treatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68929551T2 (de) 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
CA2147469C (en) 1992-11-02 2008-01-29 Ann L. Daugherty Compaction assay for assessment of respiratory disease therapy
CA2210871C (en) * 1995-02-24 2009-04-07 Genentech, Inc. Human dnase i variants
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants

Also Published As

Publication number Publication date
JP3468778B2 (ja) 2003-11-17
NZ333128A (en) 2000-08-25
EP0910647B1 (de) 2008-03-19
DE69738581D1 (de) 2008-04-30
JP2000512496A (ja) 2000-09-26
US7407785B2 (en) 2008-08-05
US20080293121A1 (en) 2008-11-27
CA2257133C (en) 2008-01-22
AU3368497A (en) 1998-01-07
ES2301180T3 (es) 2008-06-16
CA2257133A1 (en) 1997-12-18
DE69738581T2 (de) 2009-04-23
EP0910647A1 (de) 1999-04-28
US20020173025A1 (en) 2002-11-21
AU737618B2 (en) 2001-08-23
WO1997047751A1 (en) 1997-12-18
PT910647E (pt) 2008-04-15
US20050170365A1 (en) 2005-08-04
US6391607B1 (en) 2002-05-21
DK0910647T3 (da) 2008-07-21

Similar Documents

Publication Publication Date Title
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
ATE485371T1 (de) Varianten des menschlichen koagulationsfaktors vii
ATE330967T1 (de) An her2 bindende peptidverbindungen
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
DE69718734D1 (de) Bicyclische aromatische verbindungen
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE69529235D1 (de) Menschliche dnase i varianten
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE278011T1 (de) Human dnase ii
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
MX9706429A (es) Variantes de dnasa i humana.
ATE224730T1 (de) Mittel zur behandlung von pigmentierungsstörungen
UA81601C2 (ru) Полипептид фактора vii и его применения для лечения случаев кровотечения или усиление нормальной системы кровоостановки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0910647

Country of ref document: EP